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Abstract
Background:  The serine/threonine kinase PKB/Akt plays essential role in various cellular
processes including cell growth and proliferation, metabolism and cell survival. The importance of
the Akt pathway is highlighted by the mutation of various components of the pathway such as the
PTEN and PI3-kinase (P110α) in human cancers. In this paper, we employed an RNA interference
library targeting all human kinases to screen for kinases involved in the regulation of Akt activation,
in particular serine 473 phosphorylation. Here, we transfected the MDA-MB 468 breast cell line
with the human kinome siRNA library and measured Akt activation using an antibody specific for
phosphoserine 473 of Akt.
Results: The screen revealed that phosphorylation of Akt(ser473) can be regulated by more than
90 kinases. Interestingly, phosphorylation of Akt(ser473), but not thr308, can be severely reduced
by inhibition of Choline kinase activity via siRNA or small molecule inhibitors. We show here that
the regulation of Akt phosphorylation by Choline kinase is PI3K-independent. In addition, xenograft
tumors treated with Choline kinase inhibitors demonstrated a statistically significant decrease in
Akt(ser473) phosphorylation. Importantly, the reduction in phosphorylation correlates with
regression of these xenograft tumors in the mouse model.
Conclusion: High Choline kinase expression and activity has previously been implicated in tumor
development and metastasis. The mechanism by which Choline kinase is involved in tumor
formation is still not fully resolved. From our data, we proposed that Choline kinase plays a key
role in regulating Akt(ser473) phosphorylation, thereby promoting cell survival and proliferation.
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Background
Akt or Protein kinase B, is a serine/threonine kinase that
plays an important role in regulating a number of cellular
processes such as growth, metabolism and survival
(reviewed in [1]). The importance of the Akt pathway is
highlighted by the mutation of various components of the
pathway in human cancers such as the PTEN and PI3-
kinase (P110α), which occur in more than 30% of human
tumors (reviewed in [2]). In recent years, much has been
invested in the search for other Akt substrates in the hope
of understanding the different cellular processes control-
led by Akt. Currently over fifty Akt substrates have been
identified.
For Akt to achieve full activation, phosphorylation is
needed at both serine 473 (ser473) of the hydrophobic
tail and threonine 308 (thr308) of the activation motif,
upon growth factor ligation to the receptor tyrosine
kinases [3]. The extra-cellular growth signal is transduced
via the Ras protein resulting in the activation of PI3K. The
lipid kinase phosphorylates phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-tri-
sphosphate (PIP3) which acts as a secondary messenger to
recruit Akt via its PH domain to the peripheral membrane.
Similarly, PDK1 is also recruited via its PH domain to
phosphorylate thr308 of Akt. To date, there are several
candidate kinases fulfilling the role of PDK2, for the
ser473 residue, the most likely candidate being the
mTORC2 [4]. Others include DNA-PK, ILK and some
PKCs [5-9].
Choline kinase (ChoK), is a lipid kinase that phosphor-
ylates choline to generate phosphoryl choline (PCho).
PCho serves as the first step in the Kennedy pathway for
the generation of phosphatidylcholine [10], a major lipid
component of the cellular membrane. In the last few
years, high PCho and ChoK activity has been found in sev-
eral human tumor types including breast, lung, colon and
prostate [11,12]. There is a strong clinical correlation
between ChoK expression level and tumor malignancy in
breast, lung and bladder cancer [13,14]. Several reports
have also demonstrated that with the inhibition of ChoK
either by siRNA or small molecule inhibitors, there is a
marked reduction in proliferation and mitogenic proper-
ties and a decrease in breast cancer cell viability has being
reported in combination with 5-fluorouracil [15,16]. A
full understanding of how this lipid kinase and its down-
stream substrates contribute to tumorigensis has yet to be
disclosed, although some previous studies clearly corre-
late ChoK regulation with Rho A signaling, and transcrip-
tome analysis of ChoK overexpression demonstrates its
effects on cell cycle regulation and apoptosis impairment
[17-19]. Previously, it has been shown that PCho confers
mitogenic properties to mouse fibroblasts upon stimula-
tion by PDGF or FGF [20,21].
In this work, we searched for kinases that could regulate
Akt activity specifically at ser473. Using a human kinome
siRNA library, we silenced individual kinases systemati-
cally in MDA-MB 468 cells to screen for candidate kinases
that regulate Akt phosphorylation at this site using an
indirect immunofluorescent method. In our system,
MDA-MB 468 breast carcinoma cells were used for its high
endogenous Akt phosphorylation in the absence of
growth factors due to PTEN mutation. With the high con-
tent imaging system, we found that ~12% of the human
kinome could directly or indirectly regulate Akt(ser473)
phosphorylation. Of which, silencing of the ChoK,
reduces Akt(ser473) phosphorylation significantly, sug-
gesting its potential role as a regulator of PDK2.
Results
Silencing of Choline kinase A or B reduces Akt serine473 
phosphorylation in MDA-MB 468 cells
In search of kinases that could regulate Akt(ser473) phos-
phorylation, we utilized the human kinome siRNA library
from Dharmacon on the MDA-MB 468 breast cancer cell
line. After 779 serine, threonine, tyrosine and lipid
kinases were systemically knocked down, cells were
immunostained with anti-phospho-Akt(ser473) followed
by anti-rabbit conjugated to Alexa 488 secondary anti-
body. Images were acquired using automatic high content
screen fluorescent microscope (Discovery 1, Molecular
Devices) and the level of cellular Akt(ser473) phosphor-
ylation was analysed and quantified with MetaMorph
software (data not shown). Our preliminary screen dem-
onstrated that silencing of 12% of the human kinome
resulted in a 20-60% reduction in Akt(ser473) phosphor-
ylation (fig 1A) and these include mTor, PKCα and PI3K
which are known to modulate Akt phosphorylation.
Accordingly, silencing of 6 kinases resulted in more than
50% reduction in the phospho-serine (pAkt(ser473)) sig-
nal. Silencing of the lipid kinase, ChoK A resulted in 53%
reduction of pAkt(ser473) signal which is one of the
strongest inhibition in this screen. Silencing of the family
member, ChoK B, also resulted in 46% reduction in the
pAkt(ser473) signal.
The effects of ChoK A or B on Akt phosphorylation were
validated using deconvoluted siRNAs as well as the more
specific On-Target plus siRNA. As shown in fig 1B, silenc-
ing of both ChoK A and B resulted in strong reduction on
pAkt(ser473) by the western blot analysis. Using real time
PCR, successful knock down of ChoK A and B were con-
firmed (fig 1C).
ChoK regulates Akt activity
Next, we addressed how the silencing of ChoKs might
affect Akt signaling pathway. By immunoblotting for a
number of proteins, we demonstrated that in ChoK-
silenced cells, the level of pAkt(thr308) or total Akt pro-Molecular Cancer 2009, 8:131 http://www.molecular-cancer.com/content/8/1/131
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Silencing of Choline kinase A or B reduced Akt(ser 473) phosphorylation in MDA-MB 468 cells Figure 1
Silencing of Choline kinase A or B reduced Akt(ser 473) phosphorylation in MDA-MB 468 cells. A, The screen 
was set up using MDA-MB 468 cells as described in the method. The percentage pAkt(ser473) signal is calculated by obtaining 
total intensity (from fluorohore-Alexa 488) of the signal divided by total number of cells imaged. The reading is compared to 
the non-targeting siRNA transfected cells (scr, set to be 100%). B, Cells transfected with 50 nM pool (P) or deconvoluted (D1-
4) ChoK A or B siRNA for 3 days and 30 μg whole cell lysate were subjected to western blot with the indicated antibodies. 
The signals obtained from the western blot analysis were quantified with Image J program and Akt(ser473) phosphorylation 
were normalized to total Akt. The ratios were compared to scr control (set as 1) indicated by the values below the blots. C, 
siRNA were transfected to cells as (B) for 2 days. 500 ng total RNA were reverse transcribed to cDNA subjected to real time 
PCR (ABI7500) with the appropriate primer sets. Transcript levels were normalized to the scrambled control (scr). The data is 
an average of triplicate experiments.
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tein remained unchanged (fig 2A). However strong reduc-
tion in GSK3β phosphorylation, an Akt downstream
target, was observed. Inhibition of Akt phosphorylation
by silencing of ChoKs resulted in reduced Erk phosphor-
ylation, as seen with PI3K inhibitor, LY294002.
It has previously been demonstrated that the mTor com-
plex 2 (mTORC2), of which Rictor is a component, is
responsible for Akt(ser473) phosphorylation in a number
of different cell systems [4]. To assess the contribution of
the mTORC2 pathway in our system, mTor or Rictor were
silenced (fig 2B). Immunoblotting with the pAkt(ser473)
antibody demonstrated that ChoK A's effect on
Akt(ser473) phosphorylation is equivalent to Rictor's,
with more than 70% reduction following silencing of
ChoK A or Rictor.
To demonstrate that the role of ChoK in Akt activation
was not cell type specific, we performed the same silenc-
ing experiments on MDA-MB 231 cells. Two days after the
siRNA transfection, the cells were serum-starved overnight
and Akt activity was induced with the addition of Insulin-
like Growth Factor (IGF) for 15 minutes. Here, in the cells
with ChoK A or B or both silenced, stimulation with
growth factor resulted in approximately 50% less
Akt(ser473) phosphorylation compared to control cells
(fig 2C).
To further demonstrate the regulation of Akt by ChoK, we
overexpressed, either vector, ChoK A or B plasmids, in
MCF7 cells. The overexpressed lipid kinases are active as
shown in fig 2D. 24 hours posttransfection an increase in
Akt(ser473) phosphorylation was observed (fig 2E).
ChoK inhibitors inhibit ChoK activity and Akt 
phosphorylation
Next, we used small molecules inhibitors specific to
ChoKα and lesser extent to ChoKβ to confirm ChoK activ-
ity is important for Akt phosphorylation. Two different
inhibitors namely Mn58b and TCD828 were used to
inhibit ChoK activity. Treatment with 20 μM of either
inhibitors on MDA-MB 468 cells resulted in ~70% and
~85% reduction of ChoKα activity by 2 h for Mn58b and
0.5 h for TCD828 respectively (fig 3A, D). Western blot-
ting showed a reduction of Akt(ser473) phosphorylation
occurring in a dosage- and time-course dependent man-
ner (fig 3B, E). Similar observations were made in MDA-
MB 231 cells with IGF stimulation (fig 3C, F).
ChoKα regulates Akt phosphorylation down stream of 
PI3K
In order to eliminate the possibility of ChoK having an
indirect role on Akt phosphorylation for example through
its action on PI3K, we tested the generation of PIP3 in
ChoK-silenced cells. Here, we transfected a construct
expressing the PH domain of Akt fused to GFP into two
ChoK A - silenced cell lines, MDA-MB 231 and A549, a
non-small cell lung carcinoma line. The cells were starved
overnight followed by IGF stimulation. Using confocal
microscopy, PH-GFP protein displayed a ring-like staining
with plasma membrane localization in both cell lines
after IGF stimulation. This is consistent with normal gen-
eration of PIP3 and the recruitment of PH-GFP following
IGF stimulation (fig 4, left panel of each cell line). The
ring-like localization of the PH-GFP was not observed
when the cells were pre-treated with LY294002 (PI3K
inhibitor). For ChoK A - silenced cells, the staining pattern
were identical to control with plasma membrane localiza-
tion after IGF stimulation (fig 4, right panel of each cell
line). Taken together these data suggest that the role of
ChoKα in mediating Akt phosphorylation is independent
of PI3K.
Mn58b treatment slowed tumor growth through the 
inhibition of Akt phosphorylation
To further consolidate the regulation of Akt(ser473) phos-
phorylation by ChoK in vivo, tumor xenografts treated
with Mn58b were tested for the level of Akt phosphoryla-
tion. Immunosuppressed mice were injected with MDA-
MB 231 cells on each flank and tumors were allowed to
grow to 0.1 cm3. Mn58b or vehicle, were administered to
eleven mice intraperitoneally and the growth of tumor
monitored. As shown in fig 5A, tumor growth rate was sig-
nificantly slowed upon treatment with Mn58b compared
to vehicle control treated mice. Excised tumors from both
vehicle and Mn58b treatment were fixed with formalde-
hyde or frozen immediately for immunohistochemistry
staining and western blotting respectively. From the west-
ern blot (fig 5B), 4 out of 5 Mn58b treated tumors showed
a reduction in the level of Akt(ser473) phosphorylation
but not Akt(thr308), compared to vehicle treated tumors.
Statistical analysis of the normalized phosphoAkt(ser473)
signals from the western blot analysis revealed significant
difference between the vehicle and Mn58b treated tumors
with p values of 0.0075 (fig 5C). The decreased in
Akt(ser473) phosphorylation correlated with small tumor
size (fig 5A). This reduced Akt(ser473) phosphorylation
after ChoK inhibitor treatment was confirmed using IHC
staining with anti-total Akt and anti-phosphoAkt(ser473)
(fig 5D). Mn58b treated tumor sections (T7 & T9) dis-
played similar total Akt level with low phosphorylation at
the ser 473 site compared to the vehicle treated tumor sec-
tions (C6). These data demonstrate that inhibition of
ChoKα in vivo results in attenuation of Akt(ser473) phos-
phorylation, substantiating a role for this lipid kinase in
the regulation of Akt phosphorylation and tumor growth.
Discussion
In this work, we used human kinome siRNA library to
screen for kinases that positively regulate Akt phosphor-Molecular Cancer 2009, 8:131 http://www.molecular-cancer.com/content/8/1/131
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ylation at the ser473 residue in the breast cancer cell line,
MDA-MB 468. MDA-MB 468 cells have an intrinsic PTEN
mutation resulting in high endogenous Akt activity in the
absence of growth factors. The systematic silencing of
individual kinases in these cells with the RNA interference
library allows us to identify kinases that alter Akt(ser473)
phosphorylation. In combination with the high content
screening microscope, we found a total of 92 kinases that
upon knock down, resulted in 20 to 60% decrease in
Akt(ser473) phosphorylation. In the screen setup, due to
the "edge" effect of the 96 well plates, we noted that the
standard deviation of these wells were high. Hence, these
samples were not considered further. Regardless, the
screen enables us look at 500 kinases and their effect on
Akt phosphorylation.
Choline kinase regulates Akt activity Figure 2
Choline kinase regulates Akt activity. A, MDA-MB 468 cells were transfected with 50 nM of the indicated pool siRNA. 3 
days posttransfection, 50 μM LY294002 was added to scr transfected cells for 30 mins. Whole cell lysate were subjected to 
western blotting with the indicated antibodies. B, siRNA transfection and western blot were performed as (A). Percentage of 
pAkt(ser473) signal were calculated by quantifying the pAkt(ser473) normalized to total Akt on the immunoblot and compared 
to the scr control (set as 100%). C, MDA-MB 231 cells were transfected with 50 nM of indicated pool siRNA for 2 days. Cells 
were serum-starved overnight and stimulated with IGF for 15 mins. Whole cell lysates were harvested and western blot per-
formed with the indicated antibodies. The values below the blot indicate the ratio of normalized pAkt(ser473) signals quantified 
using Image J to that of scr control (set as 1). D, MCF7 were transfected with 1 μg pcDNA vector, ChoK A or B plasmids for 
24 h using Lipofectamine 2000 (Invitrogen). Cells were harvested and ChoK activity determined as described in the methods. 
E, MCF7 was transfected as in (D) and western blot with indicated antibodies.
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ChoK inhibitors inhibit ChoK activity and Akt phosphorylation Figure 3
ChoK inhibitors inhibit ChoK activity and Akt phosphorylation. A, MDA-MB 468 cells were treated with 20 μM 
Mn58b for indicated time. Lysates were harvested and ChoK activity determined as described in methods. B, MDA-MB 468 
and C, serum-starved MDA-MB 231 were treated with Mn58b for indicated time with the specified concentration. MDA-MD 
231 cells were stimulated with IGF for 15 mins. 30 μg cell lysate were subjected to western blot with the indicated antibodies. 
D, MDA-MB 468 cells were treated with 20 μM TCD828. ChoK activity was determined as described in methods. E, MDA-MB 
468 and F, serum starved MDA-MB 231 were treated with TCD828 for the indicated time with the specified concentration. 
MDA-MD 231 cells were stimulated with IGF for 15 mins. 30 μg cell lysate were subjected to western blot with the indicated 
antibodies. pAkt(ser473) signals were quantified using Image J program and normalized to respective total Akt signal. Values 
below the blots indicate the normalized Akt(ser473) phosphorylation compared to untreated control.
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Further validation had shown that ChoKα, plays an
important role in regulating Akt(ser473) phosphoryla-
tion. Our data showed that ChoK is unlikely to act on the
components upstream of Akt such as the PI3K signaling
axis. This is showed by the ability of PH-GFP fusion pro-
tein to be recruited to the peripheral membrane in the
presence of IGF stimulation in ChoK-silenced cells. These
results demonstrated that PI3K is functional and able to
generate PIP3 for the recruitment of both Akt and PDK1 as
shown with the intact Akt(thr308) phosphorylation in
these cells. Interestingly, other than the reported effects on
Akt(ser473) phosphorylation, we also observed a decrease
in Erk phosphorylation in ChoK-silenced cells. Since
silencing of ChoK does not affect PI3K activity, it is
unlikely that the reduced Erk phosphorylation is due to an
inactivation of the upstream Ras. It is however possible
that the reduction of Erk phosphorylation is due to yet
unknown effects of this lipid kinase upon the Raf/MEK
pathway, which will requires further investigation. Alter-
natively, the downstream effect on Erk signaling could
arise from the cross talk between PI3K/Akt pathway and
the Raf/MEK pathway, as shown with PI3K inhibitor,
LY294002 treatment.
Although our data from both the RNAi silencing and
small molecule inhibitor studies clearly demonstrate an
ChoKα regulation on Akt activity is PI3K independent Figure 4
ChoKα regulation on Akt activity is PI3K independent. MDA-MB 231 and A549 cells were transfected with 50 nM of 
pool siRNA targeted to scr control or ChoK A. 2 days post transfection, cells were transfected with 0.5 μg PH-GFP construct 
for 24 h followed by 8 h serum starvation and 15 mins of IGF stimulation. 50 μM LY294002 was added to scr transfected cells 
for 30 mins prior to IGF stimulation. Cells were stained with Hoechst, fixed with paraformaldehyde and mounted for fluores-
cence microscopy.
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Mn58b treatment slowed tumor growth through the inhibition of Akt(ser473) phosphorylation Figure 5
Mn58b treatment slowed tumor growth through the inhibition of Akt(ser473) phosphorylation. A, Immunosup-
pressed mice were injected with MDA-MB 231 cells on each flank and tumors were allowed to grow to 0.1 cm3. At week 3.5, 
Mn58b or vehicle, were administrated to the mice intraperitoneally and the growth of tumor monitored. B, 11 xenografts 
excised from the mice treated with vehicle (C1-6) or Mn58b (T7-11) were frozen and lysed for western blot with the indicated 
antibodies or D, fixed in paraformaldehyde and section for immunohistochemistry staining with anti-total Akt and anti-
pAkt(ser473). C, pAkt(ser473) signal was quantified with Image J program and normalized to total Akt. The ratios were input 
as scatter plot and analyzed using unpaired t-test with Prism (GraphPad). ** p < 0.05.
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interesting role of ChoK on Akt(ser473) phosphorylation,
it is unlikely that the lipid kinase phosphorylate
Akt(ser473) directly since our data with the ChoK inhibi-
tors demonstrated a distinct lag time between ChoK activ-
ity inhibition and Akt phosphorylation. Only ~50%
reduction in Akt(ser473) phosphorylation was observed
when 70% of ChoKα activity was inhibited after 2 h of
Mn58b treatment. A similar observation was made for
TCD828 treated cells with a 56% reduction in Akt(ser473)
phosphorylation after 0.5 h incubation with TCD828
which inhibited ~85% of ChoKα activity. In addition, we
did not observe a physical interaction between Akt and
ChoKα  via  co-immunoprecipitation (data not shown).
Nonetheless, the evidence presented by xenograft regres-
sion with reduced Akt(ser473) phosphorylation and
strong inhibition in Akt(ser473) phosphorylation after
prolong treatment with ChoK inhibitors strongly support
our data, suggesting a probable role of ChoKα as a regula-
tor of PDK2, controlling the phosphorylation of Akt at
ser473. Alternatively, the effect of ChoKα on Akt(ser473)
phosphorylation could also arise through the inactivation
of the Akt phosphatase. Previously, PH domain leucine-
rich repeat protein phosphatase, PHLPP was identified by
Gao  et al as the phosphatase that dephosphorylate
Akt1(ser 473) [22]. Further experiments will be required
to definitively demonstrate these unexpected properties of
ChoKα.
These findings are particularly exciting for two reasons.
Firstly, there are several potential kinases that phosphor-
ylate Akt(ser473). Of which, mTORC2 effect on Akt is sig-
nificantly reproducible in many different cell types. In our
work, we had shown that silencing of the lipid kinase,
ChoK, resulted in reduced Akt(ser473) phosphorylation
to a similar degree as observed following the silencing of
Rictor, a member of the mTORC2 complex. Secondly,
reminiscent of the regulators of the Akt pathway, there is
evidence that ChoK can serve as marker for tumor progres-
sion. It has been shown that ChoK activity and its product,
PCho, are increased in tumor cells relative to the normal
cells [12,23-27]. This has been established in tumors of
different tissue origins and in particular those derived
from the breast [28,29]. It has also been demonstrated in
vivo by NMR, where increase levels of PCho are frequently
associated with cell malignancy [30-32]. All these results
have established PCho as a malignancy marker with
potential use in cancer diagnosis [28,33]. Our data dem-
onstrate the presence of a novel cross talk between the
lipid kinase and Akt pathway
Although the precise role of ChoK in these cancer cells is
still not fully understood, it has been postulated that this
lipid kinase is likely to be upregulated in order to provide
lipid components for the actively dividing cancer cells. In
addition, the PCho appears to induce mitogenic signaling,
promoting cellular proliferation. Currently, there is an
active effort in the development of ChoK inhibitors.
Results from Mn58b, a well characterized ChoK inhibitor
with in vitro and in vivo antiproliferative and antitumoral
effect in mice xenografts provides strong support to this
concept.
Conclusions
Based on the information provided here and previous
publications, we propose that ChoK displays oncogenic
activity through activation of specific signaling pathways
that impinge on cell proliferation and survival. One
important signaling pathway affected is its interaction
with Akt in cancer cells. However, we are uncertain of how
this interaction regulates Akt other than it is required for
ser473 phosphorylation. One probable hypothesis is that
ChoK acts as an adaptor for a yet unidentified Akt(ser473)
kinase. Alternatively, it would be interesting to determine
if there is presence of any relationship between ChoK and
mTORC2 activity.
Methods
Cell line and reagents
All cell lines were purchased originally from ATCC. MDA-
MB 468, MDA-MB 231 and MCF7 were cultured in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal calf serum. Cells were incubated in 37°C
incubator with 10% carbon dioxide. ChoK A and B plas-
mids, monoclonal anti-ChoKα, Mn58b and TCD828 are
kind gifts from Prof Lacal. All reagents unless specified are
from Sigma-Aldrich (Saint Louis, MO).
Human kinome siRNA screen setup
The 779 human kinase siRNA kinome library was sup-
plied by Dharmacon as SMARTpool on 10 × 96 well
plates. Non-Targeting siRNA or scrambled siRNA (scr) is
used as negative control. 7500 MDA-MB-468 cells were
seeded in 96 well plates the day before transfection. 70
nM siRNA were transfected using Oligofactamine accord-
ing to manufracturer's instruction in triplicates. 72 hours
post transfection, cells were fixed and proceeded to indi-
rect immunofluorescent staining.
Indirect Immunofluorescent labeling
After desired period of treatment, cells were washed once
in PBS and fixed in 4% paraformaldehyde. Cells were per-
meabilised with 0.1% Triton X-100 followed by blocking
with 3% BSA/PBS for 1 h and incubation with 1:250 anti-
phospho-Akt(ser473) in 0.1% BSA/PBS overnight at 4°C.
Subsequently, cells were washed followed by the addition
of anti-rabbit secondary antibodies conjugated with Alexa
Fluor 488 for 1 h. Nuclei were counterstained with 250
ng/ml H-33342 (Molecular Probes). Fluorescent imagesMolecular Cancer 2009, 8:131 http://www.molecular-cancer.com/content/8/1/131
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were collected and analysed using either Discovery-1
(Molecular Devices) or confocal microscope.
Phospho-Akt(ser473) signal quantitation
Images of siRNA transfected cells after immunostaining
with anti-phospho-Akt(ser473) were acquired using Dis-
covery-1, high content screening fluorescent microscope,
with 10× objectives. Three fields were imaged per well and
total of 9 images were captured per kinase knock down.
Images were analysed by MetaMorph. The phospho-Akt
signal per cell per kinase knock down was calculated by
obtaining total intensity (from the Fluorohore) of the sig-
nal divided by total number of cells imaged. This reading
was compared to the non-targeting siRNA transfected cells
(scr, set to be 100%) and background fluorescence read-
ing (set to be 0%). Standard deviation was obtained from
triplicate experiments.
siRNA Transfection
siRNA targeting ChoKA, ChoKB, Akt1/2 and non-target-
ing control (scr) were purchased from Dharmacon (Dhar-
macon RNAi Technologies, Lafayette, CO) as SMARTpool
or deconvoluted set of 4. Transfections using Oligo-
fectamine (Invitrogen, San Diego, CA) were performed
following the manufacturer's instructions.
Semi-Quantitative PCR
RNA were isolated from cells using RNeasy kit from Qia-
gen. 500 ng total RNA was used to synthese complemen-
tary DNA using Superscript III first strand synthesis for RT-
PCR (Invitrogen). 2 μl of the cDNA were loaded for Real
time PCR using ABI 7500 with SYBR green mix (Applied
Biosystems) and respective primer sets. ChoKA Forward:
TAGGTTTGCCCTTGCATCTCA reverse: TCACACCCC AA
GCTTCCTCTT ChoKB Forward: GTACATCCCA AGTC
GGCCATT reverse: GCTCCTTGGTGAAAGG CATCT GAP
DH Forward: CCCTTCATTGACCTCAACTACAT reverse:
TCCTGGAAGATGGTGATGG
Transfection
Transient transfections using Lipofectamine™ 2000 (Invit-
rogen) were performed following the manufacturer's
instructions.
Inhibitor treatment
Cells were seeded the day before on 6 well dish. Mn58b or
TCD828 were added to the medium for indicated time
and concentration. For MDA-MB 231, after incubation
with inhibitors, 50 ng/ml of IGF was added for 15 mins
before whole cell lysate were harvested for western blot.
Western Blot
Cells were lysed in 1% triton lysis buffer. Protein concen-
tration was determined using BCA assay (Thermo scien-
tific). 30 μg of protein lysate were separated on 4-12% Tri-
glycine gel (Invitrogen). Protein were transferred to PVDF
membrane and immunoblotted with anti-phospho-
Akt(ser473), antiphospho-Akt(thr308), anti-phospho-
Erk1/2, anti-phospho-GSK3β (Cell Signaling Technology,
Beverly, MA), anti-ChoKα, anti-HSP60, anti-tubulin, anti-
GAPDH. Image J program was used to quantified the
western blot signal. Phospho-Akt(ser473) signal were
normalized to the respective total Akt. Difference in phos-
phorylation was obtained by comparing to scr control or
untreated cells (set as 1).
Choline kinase activity assay
ChoK activity were assayed as described in [34].
In vivo Anti-tumor Assays
Human breast tumor xenografts were established by sub-
cutaneous injection of tumor cells in each flank of nu/nu
immunosuppressed mice. Mice were kept under standard
laboratory conditions according to the guidelines of the
Spanish government. Cells were resuspended in Dul-
becco's modified Eagle's medium just before inoculation
(2 × 106 cells/0.1 ml). When tumors reached a mean vol-
ume of 0.1 cm3, mice were randomized to control and
treatment groups (6 mice per group). Treatments with
Mn58b (and vehicle for control mice) were performed
intraperitoneally for two week of treatmentseparated by 9
days. In the treatment weeks, the schedule was three doses
of 2 mg/kg each, three times in the week. Tumors were
monitored at least twice a week by measuring the major
(D) and minor (d) diameters, and tumor volume was cal-
culated as V = (D × d2)/2. The drug was well tolerated by
the mice, with no significant effects on general appearance
or behavior. Toxicity effects were confirmed by using hairy
mice, treated under similar conditions of dose and sched-
ule. No effects on fur, general appearance, or behavior
were observed. No reduction in body weight was observed
Immunohistochemistry staining
Tumors removed from mice were fixed and IHC per-
formed according to [35].
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